Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Givinostat - Italfarmaco

Drug Profile

Givinostat - Italfarmaco

Alternative Names: ITF-2357

Latest Information Update: 14 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Italfarmaco
  • Developer Italfarmaco; Radboud University
  • Class Amines; Antineoplastics; Carbamates; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Juvenile rheumatoid arthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy
  • Phase II Myeloproliferative disorders
  • Phase I/II Polycythaemia vera
  • No development reported Hereditary autoinflammatory diseases; Juvenile rheumatoid arthritis
  • Discontinued Diffuse large B cell lymphoma; Hodgkin's disease; Multiple myeloma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Dec 2017 Italfarmaco initiates enrolment in a phase II trial for Duchenne muscular dystrophy (Becker Muscular Dystrophy) in Italy (PO) (NCT03238235)
  • 12 Dec 2017 Italfarmaco completes a phase I/II trial for Duchenne muscular dystrophy (In children) in Italy (NCT01761292)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top